Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTUE541)

• DTT Name: Leukocyte surface antigen Leu-16 (CD20) DTT Info
• Gene Name: MS4A1

Molecule-Related Drug & Molecule List

11 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[1]
Glofitamab	DM45HT6	Diffuse large B-cell lymphoma	2A81	Approved	[2]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[5]
Ocrelizumab	DMEZ2KH	Diffuse large B-cell lymphoma	2A81	Approved	[6]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[7]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[8]
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[3]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[10]

42 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-8808	DMT8IAJ	Follicular lymphoma	2A80	Phase 3	[11]
PF-05280586	DMNZOCK	Cluster headache	8A81.0	Phase 3	[12]
SAIT101	DMI1R5S	Follicular lymphoma	2A80	Phase 3	[13]
AME-133v	DMIVZ3M	Non-hodgkin lymphoma	2B33.5	Phase 2	[14]
ATM AVI	DM7I56B	Bacterial infection	1A00-1C4Z	Phase 2	[5]
CAR-T cells targeting CD20	DM3RU0A	Non-hodgkin lymphoma	2B33.5	Phase 2	[15]
CD20 CAR T cells	DMQGI8R	B-cell chronic lymphocytic leukaemia	2A82.00	Phase 2	[16]
DI-Leu16-IL2	DMTLB92	Non-hodgkin lymphoma	2B33.5	Phase 2	[17]
Iodine-131-tositumomab	DMNW0DG	N. A.	N. A.	Phase 2	[18]
MT-3724	DMCNL7Z	Diffuse large B-cell lymphoma	2A81	Phase 2	[19]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[20]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[21]
REGN1979	DMSJ3Z5	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[9]
SBI-087	DMSUQFJ	Multiple sclerosis	8A40	Phase 2	[22]
TRU-015	DMHEWT7	Lymphoma	2A80-2A86	Phase 2	[23]
Veltuzumab	DM5BL4C	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[24]
4SCAR19 and 4SCAR20	DMFVTSG	B-cell lymphoma	2A86	Phase 1/2	[25]
Anti-CD19 and Anti-CD20 CAR-T Cells	DMLFB25	B-cell lymphoma	2A86	Phase 1/2	[26]
Anti-CD20 CAR-T cells	DM4WEZL	Diffuse large B-cell lymphoma	2A81	Phase 1/2	[27]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[28]
Anti-CD20-CAR-transduced T cells	DMXMK30	leukaemia	2A60-2B33	Phase 1/2	[29]
CART20	DMKGU5F	B-cell lymphoma	2A86	Phase 1/2	[30]
CD19 and CD20 CAR-T Cells	DMRJ3ND	B-cell lymphoma	2A86	Phase 1/2	[31]
CD20-Specific CAR T Cells	DMHPZ8G	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[32]
FBT-A05	DMQSF5C	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[33]
GEN3013	DMZABYH	Diffuse large B-cell lymphoma	2A81	Phase 1/2	[34]
MB-CART20.1	DMXU7P6	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[35]
PBCAR20A	DM7NKWQ	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[36]
Anti-CD19 anti-CD20 Bispecific CAR-T	DMCABUR	leukaemia	2A60-2B33	Phase 1	[37]
BM-ca	DM43RV5	Non-hodgkin lymphoma	2B33.5	Phase 1	[38]
CAR-20/19-T Cells	DM4CXE2	B-cell non-hodgkin lymphoma	2B33.5	Phase 1	[39]
CART-20 cells	DMR0Z65	Acute lymphoblastic leukaemia	2A85	Phase 1	[40]
CD20-CAR-T Cells	DM37OJN	B-cell lymphoma	2A86	Phase 1	[41]
CD20-CART	DMSJBUZ	leukaemia	2A60-2B33	Phase 1	[42]
CD20-CD19 cCAR	DMUYTW3	B-cell lymphoma	2A86	Phase 1	[43]
CD20Bi aATC	DMGXS8L	Non-hodgkin lymphoma	2B33.5	Phase 1	[44]
IGM-2323	DMMPINS	Non-hodgkin lymphoma	2B33.5	Phase 1	[45]
KITE-363	DMIZPF4	B-cell lymphoma	2A86	Phase 1	[46]
RG6035	DMAO0NI	Multiple sclerosis	8A40	Phase 1	[47]
RG7828	DMCUBZO	Haematological malignancy	2B33.Y	Phase 1	[9]
XmAb13676	DMXTOCE	B-cell lymphoma	2A86	Phase 1	[9]
Anti-CD19/20-CAR vector-transduced T cells	DM3M9OY	Acute lymphoblastic leukaemia	2A85	Clinical trial	[48]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATA2431	DM34FEA	B-cell lymphoma	2A86	Preclinical	[49]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
227Th-rituximab	DMHJM0F	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
2LM20-4	DMZD348	Autoimmune diabetes	5A10	Investigative	[5]
Anti-CD-20 mab	DMCYOPR	Discovery agent	N.A.	Investigative	[5]
Anti-CD20 engineered toxin bodies	DMEHRKA	Lymphoma	2A80-2A86	Investigative	[5]
BLX-301	DM728RW	Non-hodgkin lymphoma	2B33.5	Investigative	[5]
BVX-20-CD20	DMAVDNU	Non-hodgkin lymphoma	2B33.5	Investigative	[5]
DXL-625	DMZWAQ3	Chronic lymphocytic leukaemia	2A82.0	Investigative	[5]
MEDI-552	DMQ5S9C	Discovery agent	N.A.	Investigative	[50]

References

• [1] Clinical pipeline report, company report or official report of Genmab.
• [2] Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.
• [3] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [6] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [7] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [8] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [11] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68.
• [12] Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81.
• [13] Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163.
• [14] Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403.
• [15] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [16] ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
• [17] National Cancer Institute Drug Dictionary (drug id 599668).
• [18] Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5.
• [19] Clinical pipeline report, company report or official report of Molecular Templates.
• [20] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [21] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [22] Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208.
• [23] TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32.
• [24] Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7.
• [25] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [26] ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
• [27] ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
• [28] ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
• [29] ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
• [30] ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
• [31] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [32] ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
• [33] Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160.
• [34] DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
• [35] ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma
• [36] Clinical pipeline report, company report or official report of Precision Biosciences.
• [37] ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
• [38] BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44.
• [39] ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
• [40] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [41] ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
• [42] ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
• [43] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [44] CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
• [45] Clinical pipeline report, company report or official report of IGM Biosciences.
• [46] Clinical pipeline report, company report or official report of Gilead
• [47] Clinical pipeline report, company report or official report of Roche
• [48] ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
• [49] Clinical pipeline report, company report or official report of Atara Biotherapeutics.
• [50] Anti CD37 antibodies